GS-441524 – (1191237-69-0)

GS-441524 is a nucleoside analogue antiviral drug developed by Gilead Sciences, primarily known as the main plasma metabolite of remdesivir. It has shown significant efficacy in treating feline infectious peritonitis (FIP), a lethal disease in cats caused by feline coronavirus.

GS-441524 has a half-life of approximately 24 hours in humans and has demonstrated antiviral activity against SARS-CoV-2 in vitro, with some studies suggesting it may be more effective than remdesivir for COVID-19 treatment.

The molecule works by inhibiting viral RNA replication and is well-tolerated in cats, with minimal side effects. Recent studies have also explored shorter treatment durations, showing that a 42-day course can be as effective as the standard 84-day regimen.

The above information is displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

GS-441524 is a nucleoside analogue antiviral drug developed by Gilead Sciences, primarily known as the main plasma metabolite of remdesivir. It has shown significant efficacy in treating feline infectious peritonitis (FIP), a lethal disease in cats caused by feline coronavirus.

GS-441524 has a half-life of approximately 24 hours in humans and has demonstrated antiviral activity against SARS-CoV-2 in vitro, with some studies suggesting it may be more effective than remdesivir for COVID-19 treatment.

The molecule works by inhibiting viral RNA replication and is well-tolerated in cats, with minimal side effects. Recent studies have also explored shorter treatment durations, showing that a 42-day course can be as effective as the standard 84-day regimen.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

https://en.wikipedia.org/wiki/GS-441524
https://www.medchemexpress.com/GS-441524.html
https://www.medkoo.com/products/27317
https://www.vet.cornell.edu/departments-centers-and-institutes/cornell-feline-health-center/health-information/feline-health-topics/fip-treatment-gs-441524-now-available-us
https://pubmed.ncbi.nlm.nih.gov/39066306/

Other Names	(2R, 3R, 4S, 5R)-2-(4-aminopyrrolo[2, 1-f][1, 2, 4]triazin-7-yl)-3, 4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-carbonitrile, GS441524, EVO984
IUPAC Name	(2R, 3R, 4S, 5R)-2-(4-aminopyrrolo[2, 1-f][1, 2, 4]triazin-7-yl)-3, 4-dihydroxy-5-(hydroxymethyl)oxolane-2-carbonitrile
CAS	1191237-69-0
Molecular Weight	291.26
Molecular Formula	C12H13N5O
SMILES	C1=C2C(=NC=NN2C(=C1)[C@]3([C@@H]([C@@H]([C@H](O3)CO)O)O)C#N)N

Products

Consulting & Services

Check Out Our Research And Updates

GS-441524 – (1191237-69-0)

GS-441524 is a nucleoside analogue antiviral drug developed by Gilead Sciences, primarily known as the main plasma metabolite of remdesivir. It has shown significant efficacy in treating feline infectious peritonitis (FIP), a lethal disease in cats caused by feline coronavirus.

GS-441524 has a half-life of approximately 24 hours in humans and has demonstrated antiviral activity against SARS-CoV-2 in vitro, with some studies suggesting it may be more effective than remdesivir for COVID-19 treatment.

The molecule works by inhibiting viral RNA replication and is well-tolerated in cats, with minimal side effects. Recent studies have also explored shorter treatment durations, showing that a 42-day course can be as effective as the standard 84-day regimen.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

About Us

Products

Services

Quick Contact

Check Out Our Research And Updates

GS-441524 – (1191237-69-0)

GS-441524 is a nucleoside analogue antiviral drug developed by Gilead Sciences, primarily known as the main plasma metabolite of remdesivir. It has shown significant efficacy in treating feline infectious peritonitis (FIP), a lethal disease in cats caused by feline coronavirus.

GS-441524 has a half-life of approximately 24 hours in humans and has demonstrated antiviral activity against SARS-CoV-2 in vitro, with some studies suggesting it may be more effective than remdesivir for COVID-19 treatment.

The molecule works by inhibiting viral RNA replication and is well-tolerated in cats, with minimal side effects. Recent studies have also explored shorter treatment durations, showing that a 42-day course can be as effective as the standard 84-day regimen.

The above informationis displayed for information purpose only, and has not been reviewed by EON nor does EON attests or validates the accuracy nor does it constitutes a recommendation or validation.

Sources:

Related products

Quick Contact